节点文献

奥曲肽治疗肝硬化并上消化道出血45例临床观察

Clinical Observation of Octreotide for Treating Liver Cirrhosis Complicated with Upper Gastrointestinal Hemorrhage in 45 Cases

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 何平赵玉茹

【Author】 He Ping;Zhao Yuru;The First Affiliated Hospital of Zhengzhou University;Nanyang Road Community of Zhengzhou Ninth People’ s Hospital;

【机构】 郑州大学第一附属医院河南省郑州市第九人民医院南阳路社区卫生服务中心

【摘要】 目的探讨奥曲肽治疗肝硬化合并上消化道出血的临床疗效。方法将医院2014年6月至2016年6月收治的90例肝硬化合并上消化道出血患者随机分为对照组和观察组,各45例。在常规治疗基础上,对照组患者给予垂体后叶素,观察组患者给予奥曲肽。结果观察组总有效率为91.11%,明显高于对照组的75.56%(χ~2=3.92,P<0.05);两组Child-Pugh评分、白蛋白、血红蛋白、凝血酶原时间(PT)比较,差异均有统计学意义(t=4.19,2.16,3.14,7.69,P<0.05);观察组平均止血时间为(22.4±12.8)h,明显短于对照组的(35.9±15.4)h(t=4.52,P<0.05);观察组不良反应发生率为8.89%,明显低于对照组的26.67%(χ~2=4.86,P<0.05)。结论奥曲肽治疗肝硬化合并上消化道出血疗效确切,安全性高,值得临床推广。

【Abstract】 Objective To investigate the clinical effect of octreotide in the treatment of liver cirrhosis complicated with upper gastrointestinal hemorrhage( UGIH). Methods Totally 90 patients with liver cirrhosis complicated with UGIH in our hospital from June 2014 to June 2016 were randomly divided into the control group and the observation group,45 cases in each group. The control group was given pituitrin,while the observation group was given octreotide. Results The total effective rate of the observation group was 91. 11%,which was significantly higher than 75. 56% of the control group( χ~2 = 3. 92,P < 0. 05). The Child-Pugh score,albumin,hemoglobin,prothrombin time( PT) between the two groups were statistically significant difference( t = 4. 19,2. 16,3. 14,7. 69,P < 0. 05). The average hemostasis time of the observation group was( 22. 4 ± 12. 8) h,which were significantly shorter than( 35. 9 ± 15. 4) h in the control group( t = 4. 52,P < 0. 05). The incidence rate of adverse reactions in the observation group was 8. 89%,which was significantly lower than26. 67% in the control group( χ~2 = 4. 86,P < 0. 05). Conclusion Octreotide in the treatment of liver cirrhosis combined with UGIH has good effect and safety,it is worthy of clinical promotion.

  • 【文献出处】 中国药业 ,China Pharmaceuticals , 编辑部邮箱 ,2017年16期
  • 【分类号】R573.2;R575.2
  • 【被引频次】5
  • 【下载频次】15
节点文献中: 

本文链接的文献网络图示:

本文的引文网络